Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, p. S62, 2018. DOI: 10.25251/skin.2.62. Disponível em: https://skin.dermsquared.com/skin/article/view/458. Acesso em: 6 oct. 2025.